– June 1, 2009
June 1, 2009
View Archives Issues
-
Combined Modality Approaches to Glioblastoma
Temozolomide, administered during and subsequent to radiation therapy for patients with glioblastoma, was shown in this randomized, phase III trial to provide survival benefit when compared to those post-surgical patients treated with radiation alone. -
Things We Don't Like to Know: The High Cost of New Cancer Treatment
Median survival for patients with metastatic colorectal cancer has nearly doubled over the past 15 years with the introduction of several new drugs, including monoclonal antibodies. The increments in survival, however, have been relatively modest when placed in the context of the costs of therapy. Using a Markhov model on a hypothetical cohort of 1,000 patients, the incremental cost-effectiveness ratio per documented life-year was greater than $170,000, well beyond the usual standards for cost effectiveness. -
Factors Affecting MRI Accuracy in Breast Cancer
Age and HER2 status were shown to independently affect MRI accuracy in defining residual disease after neo-adjuvant systemic therapy for locally advanced breast cancer -
Neo-adjuvant Capecitabine/Oxaliplatin with RT for Rectal Cancer
The combination of capecitabine and oxaliplatin administered concurrently with radiation therapy as preoperative treatment for rectal cancer proves highly effective in producing complete or near-complete pathologically determined responses, and with excellent tolerability. -
Statins May Prevent Thromboembolism
Observational studies have suggested statins may not only reduce arterial cardiovascular events but also venous thromboembolism. -
Clinical Briefs in Primary Care Supplement
-
Pharmacology Watch
NSAIDs in the elderly; managing GI and CVD risk with NSAIDs; low-dose naltrexone and fibromyalgia; treating glucocorticoid-induced bone loss; FDA Actions.